{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:44Z","timestamp":1792511564102,"version":"4.5.0"},"reference-count":7,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two commercially available drug-screening assays were evaluated: the Roche kinetic interaction of microparticles in solution (KIMS) assay and the Microgenics cloned enzyme donor immunoassay (CEDIA). Urine samples from known drug-abuse patients were analyzed for amphetamines, barbiturates, benzodiazepines, benzoylecgonine, cannabinoids, LSD, methadone and opiates. Samples with discordant findings for the two assays were analyzed by gas chromatography\/mass spectrometry (GC\/MS) or gas chromatography\/electron capture detection (GC\/ECD). Amphetamines showed 96.0% concordant results, with two false positive findings by CEDIA, three by KIMS and a further two false negatives by KIMS. Barbiturates showed 99.4% concordant results, with one false negative by KIMS. Benzodiazepines showed 97.4% concordant results, with two false negatives by KIMS (cutoff 100\u03bcg\/L, CEDIA cutoff 300 \u03bcg\/L). Benzoylecgonine showed 17.8% concordant positive and 82.2% concordant negative results and no false finding by either assay. Cannabinoids showed 99.3% concordant results, with one sample negative by KIMS at a cutoff of 50\u03bcg\/L and positive by CEDIA (cutoff 25\u03bcg\/L). For LSD, 6.7% of findings were not in agreement. Methadone showed 97.5% concordant results, with two false positives by CEDIA, and one false positive and one false negative by KIMS. Opiates showed 96.9% concordant results, with no false KIMS results, but four false positives by CEDIA. The results indicate that the agreement of the CEDIA and KIMS results for the eight drugs is rather good (93.3\u2013100%).<\/jats:p>","DOI":"10.1515\/cclm.2006.087","type":"journal-article","created":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T09:14:49Z","timestamp":1144401289000},"source":"Crossref","is-referenced-by-count":9,"title":["Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study"],"prefix":"10.1515","volume":"44","author":[{"given":"Lutz","family":"Schwettmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-R\u00fcdiger","family":"K\u00fclpmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref01","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00007691-200406000-00020","article-title":"Establishment of new cloned enzyme donor immunoassays for haloperidol and bromperidol","volume":"26","author":"Yasui","year":"2004","journal-title":"Ther Drug Monit"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/clinchem\/40.5.729","article-title":"Lowering the federally mandated cannabinoid immunoassay cutoff increases true - positive results","volume":"40","author":"Huestis","year":"1994","journal-title":"Clin Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jat\/29.3.201","article-title":"Evaluation of the CEDIA heroin metabolite immunoassay with urine specimens from criminal justice drug - testing program","volume":"6","author":"Jenkins","year":"2005","journal-title":"AM J Anal Toxicol"},{"key":"ref71","first-page":"317","article-title":"Drug screening : actual status , pitfalls and suggestions for improvement","volume":"28","author":"K\u00fclpmann","year":"2004","journal-title":"J Lab Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jat\/28.7.593","article-title":"Evaluation of Roche Diagnostics Online DAT II , a new generation of assays for the detection of drugs of abuse","volume":"28","author":"Feldman","year":"2004","journal-title":"J Anal Toxicol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jat\/29.3.193","article-title":"Urine benzodiazepine screening using Roche online KIMS immunoassay with \u03b2 - glucuronidase hydrolysis and confirmation by gas chromatography - mass spectrometry","volume":"29","author":"Klette","year":"2005","journal-title":"J Anal Toxicol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jat\/27.4.205","article-title":"Evaluation of immunochemical drug screening of whole blood samples A retrospective optimization of cutoff levels after confirmation analysis on GC - MS and HPLC - DAD","volume":"27","author":"Kroener","year":"2003","journal-title":"J Anal Toxicol"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2006.44.issue-4\/cclm.2006.087\/cclm.2006.087.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2006.087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T22:47:17Z","timestamp":1619045237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2006.087\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":7,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1515\/cclm.2006.087","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}